PGEN Stock — Precigen Inc.: Cash, EV, Pipeline

What they do

We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.47

Market cap

$1,602.7M

Cash

$51.0M

Enterprise value

$1,646.0M

Balance sheet

Cash	$51.0M
Debt	$94.3M
Net cash	-$43.3M
Enterprise value	$1,646.0M
Basic shares	358.6M shares
Fully diluted shares	431.9M shares
Fully diluted market cap	$1,930.7M
Cash per share	$0.14
Quarterly burn	$17.8M
Cash runway	2.1 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

358.0M

Pre-funded warrants

0.0M

Options

17.9M

RSUs

3.3M

Warrants

52.7M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

431.9M

Cap table as of 2026-09-30.

Price history

Loading PGEN daily closes…

Loading price history…

Next catalyst

PRGN-2009 plus Pembrolizumab · Dec 23, 2026 - Feb 3, 2027 in 7 wks · Phase 2 · Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 23, 2026 - Feb 3, 2027 in 7 wks	PRGN-2009 plus Pembrolizumab	Phase 2	Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy	Q4 2026 Est. Dec 23, 2026 · PCD + 6 wks (Dec 9-Dec 31)

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PRGN-2009

Phase 2 · Active Modality: off-the-shelf adenoviral vector immunotherapy (AdenoVerse)

Target HPV

Partnerships National Cancer Institute: CRADA (Phase 2 development)

Indications

Recurrent/metastatic cervical cancer (Phase 2)
Newly diagnosed HPV-associated oropharyngeal cancer (Phase 2)

Status note In Phase 2 for HPV-associated cancers under NCI CRADA: R/M cervical cancer in combination with pembrolizumab; two newly-diagnosed oropharyngeal cancer trials (with pembrolizumab, and with neoadjuvant chemotherapy).

PRGN-3006

Phase 1 · Active Modality: autologous CAR-T (UltraCAR-T platform)

Target CD33 (Siglec-3)

Indications

Relapsed/refractory AML (Phase 1)
High-risk MDS (Phase 1)

Status note Phase 1b enrollment complete. FDA Fast Track designation and Orphan Drug Designation in AML; company seeking strategic partnership to advance the program.

PRGN-3005

Phase 1 · Active Modality: autologous CAR-T (UltraCAR-T platform)

Target MUC16 (Mucin 16, unshed portion)

Indications

Advanced recurrent platinum-resistant ovarian / fallopian tube / primary peritoneal cancer (Phase 1)

Status note Phase 1 dose escalation completed; enrollment in Phase 1b paused as part of Aug 2024 strategic prioritization.

PRGN-3007

Phase 1 · Active Modality: autologous CAR-T (next-generation UltraCAR-T platform)

Target ROR1

Indications

ROR1+ hematologic malignancies (Phase 1)
ROR1+ solid tumors (TNBC) (Phase 1)

Status note Phase 1 enrollment paused as part of Aug 2024 strategic prioritization.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Zopapogene imadenovec (Zopa)
Lead indication	Recurrent Respiratory Papillomatosis
Lead phase	Phase 4
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06157151	Phase 2	Recruiting	Sponsor	PGEN	—	Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy	Q4 2026 Est. Dec 23, 2026 · PCD + 6 wks (Dec 9-Dec 31)
NCT04724980	Phase 2	Active, not recruiting	Sponsor	PGEN	—	Recurrent Respiratory Papillomatosis; Papillomavirus Infections; Papillomaviridae	—
NCT03927261	Phase 1	Active, not recruiting	Sponsor	PGEN	—	Acute Myeloid Leukemia; Myelodysplastic Syndromes	—
NCT03907527	Phase 1	Active, not recruiting	Sponsor	PGEN	—	Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma	—
NCT06538480	Not disclosed	Recruiting	Sponsor	PGEN	—	Recurrent Respiratory Papillomatosis; Papillomavirus Infection; Papillomaviridae	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Precigen, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	6,417,500	no change	1.66%	2026-08-14
Boxer Capital	5,150,000	+1,650,000	2.21%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

PGEN — Precigen Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

PGEN — Precigen Inc.